QIAGEN N.V. Files 6-K for Q4 2024 Period
Ticker: QGEN · Form: 6-K · Filed: Feb 7, 2025 · CIK: 1015820
| Field | Detail |
|---|---|
| Company | Qiagen N.V. (QGEN) |
| Form Type | 6-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, quarterly-update, foreign-private-issuer
Related Tickers: QGEN
TL;DR
QIAGEN (QGEN) dropped a 6-K for Q4 2024, check it for the latest numbers.
AI Summary
QIAGEN N.V. filed a Form 6-K on February 7, 2025, reporting on its quarterly period ended December 31, 2024. The filing includes information about the company's financial reporting and operations as a foreign private issuer. QIAGEN N.V. is incorporated in the Netherlands and its fiscal year ends on December 31.
Why It Matters
This filing provides investors with updated information on QIAGEN N.V.'s performance and regulatory disclosures for the end of the 2024 fiscal year.
Risk Assessment
Risk Level: low — This is a routine quarterly filing (6-K) that provides standard financial and operational updates.
Key Players & Entities
- QIAGEN N.V. (company) — Registrant
- 001-38332 (company) — SEC File Number
- 20250207 (date) — Filing Date
- 20241231 (date) — Reporting Period End Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
What period does this specific 6-K filing cover?
This Form 6-K filing covers the quarterly period ended December 31, 2024.
What is QIAGEN N.V.'s SEC File Number?
QIAGEN N.V.'s SEC File Number is 001-38332.
When was this Form 6-K filed?
This Form 6-K was filed on February 7, 2025.
Where is QIAGEN N.V. headquartered?
QIAGEN N.V. is headquartered in Venlo, The Netherlands.
Filing Stats: 746 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2025-02-06 18:35:23
Filing Documents
- a2024q4prform6-k.htm (6-K) — 24KB
- exhibit9912024q4pressrelea.htm (EX-99.1) — 365KB
- qiagen_logo.jpg (GRAPHIC) — 68KB
- 0001015820-25-000015.txt ( ) — 483KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date February 6, 2025 4 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press Release dated February 5, 2025 5